
# Oxytocin deficiency is associated with hyperphagia & weight gain in hypothalamic & common obesity: a first-in-humans proof-of-concept study

Hoong-Wei Gan<sup>a,b</sup>, Clare Leeson<sup>c</sup>, Helen Aitkenhead<sup>c</sup>, Helen Spoudeas<sup>b</sup>, Juan Pedro Martinez-Barbera<sup>d</sup>, Mehul Dattani<sup>a,b</sup>

Great Ormond Street NHS Hospital for Children **NHS Trust** 

<sup>a</sup>Genetics & Genomic Medicine Programme, UCL GOS Institute of Child Health, UK | <sup>b</sup>The London Centre for Paediatric Endocrinology & Diabetes, Great Ormond Street Hospital for Children NHS Foundation Trust, UK | Department of Chemical Pathology, Great Ormond Street Hospital for Children NHS Foundation Trust | dDevelopmental Biology & Cancer Programme, UCL GOS Institute of Child Health, UK \*Nothing to disclose



#### INTRODUCTION


- Hypothalamic obesity (HyOb) is a syndrome of intractable morbid obesity seen in congenital (e.g. septo-optic dysplasia (SOD)) and acquired (e.g. suprasellar tumours) hypothalamic damage.
- It is commonly associated with the hypothalamic syndrome (panhypopituitarism, autism, sleep & temperature disturbances).
- Its pathophysiology has been attributed to hyperphagia and hyperinsulinaemia.
- More recently the wider role of oxytocin (OXT) in regulating appetite and weight has emerged from animal studies and pilot trials of intranasal OXT in humans with common obesity.
- We aimed to determine if hypooxytocinaemia and hyperinsulinaemia were more prevalent in HyOb compared to common obesity and to examine the relationship between OXT concentrations, appetite and weight.

#### **METHODS**


- Multiway case-control study, 4 subcohorts:
- Hypothalamic obese (HyOb, BMI >+2SDS) congenital (SOD) vs. acquired (suprasellar tumour)
- Hypothalamic lean (HyLean, BMI ≤+2SDS) congenital vs. acquired
- Common obese (Ob)
- Lean controls (Lean)
- Independent variables: Age, sex, height/ weight/ BMI SDS, Tanner stage, endocrine morbidity score (EMS), frequency of hypothalamic syndrome features (autism, temperature dysregulation, sleep disturbances)
- <u>Dependent variables:</u> Dykens' Hyperphagia Questionnaire Score (DHQS), fasting and 2-hour oral glucose tolerance test-stimulated Insulin and OXT concentrations using internally validated ELISA
- Statistical analyses using SPSS v22


#### **RESULTS** HyOb HyLean Common Lean Obese controls (n=21)(n=15)SOD SOD Tumour Tumour (n=17)(n=11)(n=25)(n=4)12.9 14.2 10.2 14.1 11.5 10.3 Age (8.9-14.9)(9.1-18.0)(10.9-14.5)(9.1-13.8)(7.3-12.3)(6.1-13.3)Female 11 (44%) 12 (71%) 6 (55%) 9 (43%) 4 (27%) 2 (50%) 1 (1-3) 2 (1-4) 1 (1-3) 2 (1-4) 3 (2-5) 2 (1-3) Tanner stage -0.9 -1.8 -0.7 0.0 Height SDS -0.4 0.4 (-1.2-0.8)(-1.8-1.0)(-2.0--0.9)(-2.4-1.7)(-1.8--0.4)(-1.2-1.1)Weight 2.2 2.0 0.0 1.0 2.3 8.0 **SDS**\*\*\* (1.5-2.7)(-0.9-1.5)(1.4-2.8)(-1.0-0.5)(-0.1-1.2)(1.6-3.1)BMI SDS\*\*\* 2.6 1.7 2.7 8.0 2.8 1.0 (-0.8-1.7)(2.4-3.2)(2.4-2.9)(0.6-1.8)(1.1-1.8)(2.4-3.2)Autism\*\*\* 7 (36.8%) 1 (6.3%) 5 (55.6%) 0 (0.0%) 1 (5.0%) 0 (0.0%) 15 (71.4%) 16 (80.0%) 8 (50.0%) 1 (11.1%) 4 (100.0%) 12 (80.0%) Learning difficulty\*\*\* 4 (25.0%) 9 (42.9%) 7 (70.0%) 0 (0.0%) 1 (5.0%) 0 (0.0%) Sleep problems\*\*\* 1 (11.1%) 0 (0.0%) 1 (6.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Temperature dysregulation \*\*\*p<0.001

### Hyperphagia is not unique to HyOb




### Hyperinsulinaemia is not more severe in HyOb





# **OXT** is associated with an increased appetite



## CONCLUSIONS

- Hyperphagia and hyperinsulinaemia are common to both HyOb and common obesity, and therefore unlikely to be primary drivers of HyOb.
- First-in-humans study supporting the role of OXT as an anorexigen with additional possible effects on weight & BMI.
- No correlation between OXT concentrations and other features of the hypothalamic syndrome or diabetes insipidus
- 6.5% had impaired glucose tolerance and 1 patient (1.1%) had frank type 2 diabetes.
- Further recruitment needed to power study sufficiently, with possible need for OXT trials in HyOb and common obesity.

References: 1. Lustig RH et al. J Clin Endocrinol Metab 2003; 88:2586-92. 2. Dykens EM et al. Obesity (Silver Spring) 2007; 15:1816-26. 3. Deblon et al. PLoS ONE 2011; 6:e25565. 4. Lawson EA et al. Obesity (Silver Spring) 2015; 23:950-6.



Pituitary and Neuroendocrinology Hoong-Wei Gan

